Futibatinib, a non‐ATP‐competitive FGFR1–4 inhibitor that binds covalently and irreversibly to the conserved cysteine in the P‐loop of the FGFR kinase domain, has resulted in remission in various cancers, including cholangiocarcinoma, gastric cancer, uroepithelial cancer, central nervous system tumors, head and neck cancer, and breast cancer, with the greatest activity in intrahepatic cholangiocarcinoma with FGFR2 rearrangements or fusions. Here, FGFR2 is linked to central nervous system cancer.